Arvee Laboratories (India) Ltd. provides chemical products, which includes polymer modifiers, contrast media and drug intermediates. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2018-02-22. The firm is primarily engaged in the manufacturing of Polymer Modifiers, Contrast Media Intermediates and Drug Intermediates. The Company’s Polymer Modifiers include 5-Sulfoisophthalic Acid Mono Sodium Salt, Dimethyl 5-Sodiosulfoisophthalate and 5-Sulfoisophthalic Acid Mono Lithium Salt. Its Contrast Media Intermediates include 5-Nitroisophthalic acid, 5-Aminoisophthalic acid, Dimethyl 5-Nitroisophthalate, 5-Hydroxyisophthalic acid, Monomethyl 5-Nitroisophthalate, 3,5-Diamino Benzoic Acid, Dimethyl 5-Aminoisophthalate and 3,5-Dinitrobenzoic acid. Its Drug Intermediates include 2-Acetyl Thiophene, Thiophene-2-Carboxaldehyde, 4-Amino Pyridine and 2-Chloro-5-Nitrobenzoic Acid.
Loading chart…
Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:
The headline call - descriptive label, conviction, and the synthesis behind it.
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Forensic and governance risk pointers, severity-ranked.
Solvency and earnings-quality score.
Quarter-by-quarter earnings-call briefs - what changed and why.